Lipid-Loaded Microglia (Foam Cells)

Lipid-Loaded Microglia (Foam Cells)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Lipid-Loaded Microglia (Foam Cells)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Gene Category</td>
<td>Upregulated</td>
</tr>
<tr>
<td class="label">Lipid metabolism</td>
<td>Plin2, Lpl, Fabp5</td>
</tr>
<tr>
<td class="label">Phagocytosis receptors</td>
<td>Cd36, Trem2</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>Tnf, Il1b</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hexb, Ctsd</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>LDAM</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Lipid dysregulation</td>
</tr>
<tr>
<td class="label">Key markers</td>
<td>PLIN2+, LPL+</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Lipid storage</td>
</tr>
<tr>
<td class="label">TREM2 dependence</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Phagocytosis</td>
<td>Impaired</td>
</tr>
</table>

Introduction

Lipid-Loaded Microglia (Foam Cells)

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Lipid-Loaded Microglia (Foam Cells)</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000129](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)</td>
</tr>
<tr>
<td class="label">Gene Category</td>
<td>Upregulated</td>
</tr>
<tr>
<td class="label">Lipid metabolism</td>
<td>Plin2, Lpl, Fabp5</td>
</tr>
<tr>
<td class="label">Phagocytosis receptors</td>
<td>Cd36, Trem2</td>
</tr>
<tr>
<td class="label">Inflammation</td>
<td>Tnf, Il1b</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hexb, Ctsd</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>LDAM</td>
</tr>
<tr>
<td class="label">Trigger</td>
<td>Lipid dysregulation</td>
</tr>
<tr>
<td class="label">Key markers</td>
<td>PLIN2+, LPL+</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Lipid storage</td>
</tr>
<tr>
<td class="label">TREM2 dependence</td>
<td>Partial</td>
</tr>
<tr>
<td class="label">Phagocytosis</td>
<td>Impaired</td>
</tr>
</table>

Introduction

Lipid-loaded microglia, also known as foam cells, are a specialized subset of microglia that have accumulated large amounts of intracellular lipid droplets. These cells represent a distinct activation state characterized by metabolic reprogramming and are increasingly recognized as important players in neurodegenerative diseases, particularly Alzheimer's disease (AD)[@foam2020]. Foam cells in the brain share morphological and functional similarities with atherosclerotic foam cells, representing a final common pathway for lipid handling in chronic inflammatory conditions[@lipid2019].

The term "foam cell" derives from the vacuolated, foamy appearance these cells exhibit under microscopy due to accumulated lipid droplets. In the brain, lipid-loaded microglia arise from chronic exposure to amyloid-beta, APOE4-associated lipid dysregulation, and ongoing neuroinflammation[@apoe2021]. These cells are now recognized as a key therapeutic target, particularly through the TREM2 pathway.

<!-- multi-taxonomy-enrichment -->

Multi-Taxonomy Classification

Taxonomy Database Cross-References

Morphology & Electrophysiology

• Morphology: microglial cell (source: Cell Ontology)
• Morphology can be inferred from Cell Ontology classification

PanglaoDB Marker Cross-References

• Unknown (PanglaoDB):

External Database Links

• [Cell Ontology (CL:0000129)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000129)
• [OBO Foundry (CL:0000129)](http://purl.obolibrary.org/obo/CL_0000129)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)
• [PanglaoDB](https://panglaodb.se/)

Discovery and scRNA-Seq Characterization

Landmark Studies

Lipid-droplet-accumulating microglia (LDAM) were first comprehensively characterized by Marschallinger et al. (2020) using single-cell RNA sequencing[@marschallinger2020]. This study revealed LDAM as a distinct microglial population with unique transcriptional signature:

Key LDAM Markers (from scRNA-seq):

• PLIN2 (Perilipin 2) - Primary lipid droplet marker
• LPL (Lipoprotein Lipase)
• FABP5 (Fatty Acid Binding Protein 5)
• CD36 (Scavenger Receptor)
• TLR2 (Toll-like Receptor 2)
• APOE (Apolipoprotein E)

Transcriptional Profile

Single-cell analysis reveals LDAM express a unique gene signature[@marschallinger2020][@singlecell2021]:

Formation Mechanism

Cellular Pathways

LDAM formation involves several interconnected pathways[@cellular2019]:

Role of APOE

APOE4 isoform significantly promotes LDAM formation[@apoe2021a]:

• Reduced lipid efflux capacity
• Enhanced lipid uptake
• Increased inflammatory response
• Synergistic with TREM2 risk variants

LDAM vs. DAM

While both LDAM and Disease-Associated Microglia (DAM) arise in neurodegeneration, they represent distinct states[@comparative2022]:

LDAM in Disease Context

Alzheimer's Disease

LDAM are particularly prominent in AD brain[@ldam2021]:

• Accumulate around amyloid plaques
• Correlate with disease severity
• Associated with APOE4 carrier status
• Contribute to chronic neuroinflammation

Aging

LDAM increase with normal aging[@marschallinger2020]:

• Age-related lipid metabolism decline
• Accumulation of oxidized lipids
• Precedes pathological changes
• Represents "primed" state for disease

Other Neurodegenerative Conditions

LDAM-like cells found in:

• [Parkinson's disease](/diseases/parkinsons-disease) Multiple sclerosis
• Huntington's disease
• Traumatic brain injury

Metabolic Dysfunction

Glycolytic Shift

LDAM exhibit metabolic reprogramming[@microglial2020]:

• Increased glycolysis
• Reduced oxidative phosphorylation
• Impaired mitochondrial function
• Lactate accumulation

Lysosomal Dysfunction

Key feature of LDAM[@lysosomal2019]:

• Lysosomal lipid accumulation
• Impaired autophagic flux
• Cathepsin dysfunction
• Cellular stress responses

Therapeutic Implications

Targeting LDAM

Clinical Approaches

• Pioglitazone: PPARγ agonist in clinical trials
• CS1R antagonists: Deplete/replace LDAM
• Gene therapy: Modulate lipid metabolism genes

See Also

• [Microglial Polarization
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
• APOE and Neurodegeneration
• Alzheimer's Disease Microglia
• [Disease-Associated Microglia](/cell-types/alzheimers-microglia)

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving Lipid-Loaded Microglia (Foam Cells) discovered through SciDEX knowledge graph analysis: